1-acetyl-N-(4-fluorobenzyl)piperidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-acetyl-N-(4-fluorobenzyl)piperidin-4-amine
• 英文别名: 1-[4-[(4-fluorophenyl)methylamino]piperidin-1-yl]ethanone
• 化学式: C₁₄H₁₉FN₂O
• mdl: MFCD01452356
• 分子量: 250.31
• InChiKey: FDCNRTNMLPCSNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS
  申请人：Uldam Henriette Kold

  公开号：US20090082342A1

  公开（公告）日：2009-03-26

  Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.

  本文披露了公式(I)、(II)、(III)、(IV)和(V)化合物的分离形式，或其药物可接受的盐、前药、水合物、溶剂化物、多晶形或酯。本文还披露了抑制5-羟色胺受体活性的方法、抑制5-羟色胺受体激活的方法，以及缓解或治疗各种疾病状况和副作用的方法。
• CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS
  申请人：Acadia Pharmaceuticals Inc.

  公开号：US20140349976A1

  公开（公告）日：2014-11-27

  As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities.

  本文披露了pimavanserin与改善一种或多种胆碱能异常的药物联合使用，可以对药物的疗效产生协同作用。本文还披露了包含pimavanserin与改善一种或多种胆碱能异常的药物联合使用的组合物。此外，还披露了改善或治疗由一种或多种胆碱能异常所特征的疾病情况的方法，其中可以包括联合使用pimavanserin和改善一种或多种胆碱能异常的药物进行治疗。